HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.